IceCure Showcases ProSense® Cryoablation and Sponsors Hands-On Courses at SBI 2025 Symposium
IceCure Medical Ltd. (Nasdaq: ICCM), the company behind the minimally invasive ProSense® cryoablation system, announced its successful participation in the Society of Breast Imaging (SBI) 2025 Breast Imaging Symposium, held April 24–27 in Colorado Springs, Colorado.
IceCure sponsored two breast cryoablation training courses conducted by the SBI on April 24 and 26. Both sessions — which offered hands-on experience with the ProSense® system — were completely sold out. The high turnout reflects a growing interest among radiologists to integrate cryoablation into their clinical practices and highlights the increasing adoption of ProSense® as medical societies expand their education around this minimally invasive technology.
In addition to its sponsorship, IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a recognized expert in women’s imaging and cryoablation techniques. Dr. Ward, who holds multiple leadership roles at the Warren Alpert Medical School of Brown University and Women & Infants Hospital, led discussions on the rationale and clinical approach behind breast cryoablation. He also shared insights from his published work using ProSense®, including a notable article in the American Journal of Roentgenology titled “Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials.”
IceCure CEO Eyal Shamir commented on the strong alignment between the company’s mission and the SBI’s focus on early detection and intervention. “Once diagnosed by radiologists, ProSense® can quickly and minimally invasively destroy tumors before they destroy lives,” he said. Shamir emphasized the importance of introducing ProSense® to thousands of U.S. breast imaging professionals, particularly as the company anticipates potential regulatory approval for breast cancer treatment in the United States.
About the Society of Breast Imaging (SBI)
The Society of Breast Imaging is comprised of over 4,000 radiologists, physicists, and medical technologists committed to advancing breast imaging through evidence-based, compassionate care. SBI members promote early detection and treatment practices that minimize the impact of breast cancer while improving patient outcomes.
About ProSense® Cryoablation System
ProSense® is a portable, minimally invasive cryoablation system that utilizes liquid nitrogen to freeze and destroy tumors in situ. The technology produces large and effective ablation zones for a wide range of tumor types, including benign and malignant lesions in the breast, kidney, lung, and liver. The system is designed to improve patient recovery times, reduce pain and complications, and enable outpatient procedures in clinical office settings — offering patients a safe and efficient alternative to traditional surgery.
About IceCure Medical
IceCure Medical Ltd. (Nasdaq: ICCM) develops and markets liquid-nitrogen-based cryoablation solutions to treat tumors through freezing, with a focus on breast, kidney, bone, and lung cancers. Its flagship system, ProSense®, is cleared for use in several global markets, including the U.S., Europe, and Asia, and offers a less invasive alternative to conventional surgical tumor removal. The company is dedicated to expanding access to cryoablation as a safer, faster, and more cost-effective cancer treatment option.
Forward-Looking Statements
This press release includes forward-looking statements under U.S. securities laws, including expectations around IceCure’s product development, regulatory prospects, market adoption, and clinical performance. These statements are based on current assumptions and involve risks and uncertainties that may cause actual results to differ materially. Risk factors include revenue projections, funding needs, market acceptance, legal and regulatory changes, intellectual property protection, and geopolitical events—particularly those impacting Israel. For more information, refer to IceCure’s filings with the SEC, including its Annual Report on Form 20-F for the year ended December 31, 2024, filed on March 27, 2025. IceCure undertakes no obligation to revise these statements unless required by law.